House Resolution 880 is a nonbinding resolution that designates September 28 through October 4, 2026 as Frontotemporal Degeneration (FTD) Awareness Week in Illinois. The resolution explains that FTD is an underdiagnosed neurodegenerative disease that affects behavior, decision-making, personality, language, and movement, and it emphasizes that the disease is often mistaken for Alzheimer’s disease, Parkinson’s disease, or psychiatric conditions. It also notes that there is currently no cure or treatment to slow the disease’s progression.
The resolution highlights the personal story of Kara Kirby, who was diagnosed with behavioral-variant FTD at age 29 and died in 2023 at age 33, as an example of the need for greater awareness, support, and earlier diagnosis. It states that similar awareness efforts have been adopted in other states and frames the observance as a way to increase understanding of a disease that is described as misunderstood, misdiagnosed, and underfunded.
Impact
HR0880 does not amend the Illinois Compiled Statutes or create regulatory requirements; instead, it establishes a state observance through a House resolution. Its practical effect is symbolic and educational, directing public attention toward FTD and encouraging awareness among the public and medical community. The resolution may also help support advocacy, outreach, and recognition efforts for patients, caregivers, and organizations focused on neurodegenerative disease.
Sentiment
The overall sentiment around the resolution is strongly supportive and commemorative. The bill’s findings present FTD as a serious, often overlooked illness and argue that a formal awareness week is needed to improve understanding and support. No votes or committee transcripts were provided, but the text itself reflects a consensus-oriented, advocacy-driven measure with no apparent opposition expressed in the available record.
Contention
No specific points of contention are identified in the available materials. Because the measure is a resolution rather than a substantive policy bill, there is little obvious basis for disagreement beyond the general question of whether state recognition efforts should be used for disease awareness. The resolution’s emphasis on a named individual’s experience, the lack of a cure, and the comparison to other states suggests the main purpose is awareness rather than controversy.